Supplementary Table. Demographic Characteristics of V-safe Respondents Who Received Janssen COVID-19 Vaccine and Completed at Least One Health Survey During the 7 Days After Vaccination, March 2–April 12, 2021

Details

• Alternative Title:
  Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — U.S. March–April 2021: Supplementary Table. Demographic Characteristics of V-safe Respondents Who Received Janssen COVID-19 Vaccine and Completed at Least One Health Survey During the 7 Days After Vaccination, March 2–April 12, 2021
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Subjects:
  Ad26COVS1 Adolescent Adult Adverse Drug Reaction Reporting Systems Aged Aged, 80 And Over Child Child, Preschool COVID-19 Vaccines Drug-Related Side Effects And Adverse Reactions Drug Approval Female Humans Infant Infant, Newborn Male Middle Aged Product Surveillance, Postmarketing Risk Assessment Safety-Based Drug Withdrawals Sinus Thrombosis, Intracranial Young Adult

  More +
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Figures
• Genre:
  Tables
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  70
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:eae6745e045b0dda0c3c153e8888a4bdd16ac8ad99dc6748c26499b415ce38433752fe2601bbe4c913540fec50a3fab609798dd7fc4dae7ebc2a3a0a40fe1012
• Download URL:
  https://stacks.cdc.gov/view/cdc/105473/cdc_105473_DS1.pdf
• File Type:
  [PDF - 104.68 KB ]